Fecal Microbiota Transplantation for Liver Failure

The Clinical Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Acute-on-chronic Liver Failure

To investigate the safety, adverse reactions and therapeutic effects of fecal microbiota transplantation on patients with liver failure;to investigate the effect of fecal microbiota transplantation on the intestinal microecology and "gut-liver axis immune system" of liver failure, and further optimization of fecal microbiota transplantation technology.

Inclusion Criteria:

• Patients willing to sign informed consent
• Patients aged 18-65
• According to the diagnosis standard of liver failure in the guide for diagnosis and treatment of liver failure (2018 Edition), the eligible patients are included, that is, on the basis of chronic liver disease, the syndrome with acute jaundice deepening and coagulation dysfunction as the manifestation of liver failure caused by various inducements can be combined with complications such as Hepatoencephalopathy, ascites, electrolyte disorder, infection, hepatorenal syndrome, hepatopulmonary syndrome, etc And extrahepatic organ failure. The patient's jaundice deepened rapidly, the serum TBIL ≥ 10 × ULN or the daily rise ≥ 17.1 μ mol / L; there was bleeding, PTA ≤ 40% (or INR ≥ 1.5)

Exclusion Criteria:

• Patients with severe heart failure, COPD, cerebrovascular accident, nephrotic syndrome, etc;
• Patients with gastrointestinal bleeding, pulmonary infection, septicemia, etc
• Patients with liver cancer, lung cancer, lymphoma and other malignant tumors
• Patients taking anticoagulants, mental diseases and immune diseases for a long time
• Pregnant or lactating women.